Epidemiology and Transmission Routes
Malaria is characterized by high susceptibility, with hundreds of millions of cases globally. In tropical climates, P. falciparum is absolutely dominant, whereas P. vivax and P. malariae are more frequently diagnosed in temperate regions. Infections caused by P. ovale occur sporadically. In non-endemic regions, cases are typically imported, though local transmission foci can occasionally emerge in southern latitudes.
The primary transmission mechanism is vector-borne. Infection occurs via the bite of an infected female Anopheles mosquito. A parenteral route is significantly less common, occurring via blood transfusion or the use of inadequately sterilized medical instruments.
Pathogenesis and Malaria Paroxysm
The incubation period is highly variable, ranging from several weeks to a year, and can extend up to 20 months in tertian malaria. Incubation ends when the parasites enter the bloodstream.
Clinical manifestations are closely linked to the cycle of erythrocytic schizogony. Massive destruction of infected erythrocytes releases pyrogenic substances into the blood: cellular debris, merozoites, and pathogen metabolites. This triggers the classic malaria paroxysm, which proceeds through a strict sequence of phases:
- Intense chills accompanied by severe headache.
- Sudden temperature spike to 39–40 °C (102–104 °F) or higher.
- Rapid temperature drop (lysis) accompanied by profuse sweating and severe weakness.
Depending on the species, paroxysms may occur daily or recur at 1- to 2-day intervals. Prolonged disease leads to damage of parenchymal organs, including the liver, spleen, and kidneys.
Features of Falciparum Malaria
The most dangerous form is falciparum malaria, caused by P. falciparum. Its key feature is that the parasite infects erythrocytes of any age, and its replication occurs predominantly in the microvasculature of internal organs rather than in peripheral blood.
Pathological processes involve massive intravascular hemolysis and the formation of parasitic thrombi that occlude capillaries. The situation is exacerbated by an immunopathogenic component: developing autoimmune reactions destroy even uninfected erythrocytes.
Severe complications include blackwater fever (hemoglobinuric fever), acute kidney injury, and central nervous system involvement (cerebral malaria due to microcirculatory impairment in the brain). Case fatality for this form is approximately 1%.
Immunity and Laboratory Diagnostics
Acquired immunity to malaria is non-sterile, unstable, and strain-specific (targeting a specific species and parasite stage), failing to protect against reinfection. IgG antibodies provide a protective role by enhancing phagocytosis. The parasite actively evades the immune response through developmental stage transitions and antigenic variation. However, natural genetic resistance exists. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, Duffy blood group negativity, or hemoglobinopathies (such as sickle cell trait) have a lower susceptibility.
The primary diagnostic method is microscopy. Blood smears ("thick drops" and thin films) are stained with Romanowsky-Giemsa or Wright's stain (parasite nuclei stain red, cytoplasm blue). In a thick smear, erythrocytes lyse, but pathogen concentration is maximal. Diagnostic feature of P. falciparum: in uncomplicated infections, only ring-form trophozoites and crescent-shaped gametocytes are found in peripheral blood. Additional methods include PCR, DNA hybridization, and serology (IFA, indirect hemagglutination assay, ELISA).
Principles of Treatment and Prevention
Antimalarial drugs are classified by their site of action: they may target sexual or asexual stages (schizonticides, gametocytocides, sporozoiticides). Treatment relies on quinine, mefloquine, chloroquine, primaquine, pyrimethamine, and artemisinin derivatives (artesunate, artemether).
Prevention consists of two pillars:
- Public health measures: mosquito vector control and case detection (patients and carriers).
- Individual measures: chemoprophylaxis in endemic zones. Options include mefloquine (if resistance to chloroquine by P. falciparum is a risk), savarine (proguanil + chloroquine), or a combination of chloroquine and primaquine.
Genetically engineered vaccines targeting specific parasite forms (sporozoites, merozoites, or gametocytes) are in active development.